AMRN logoAMRN
Amarin Corp - ADR

30,655
Loading...
Loading...
News
all
press releases
Prothena (PRTA) Up 17.6% Since Last Earnings Report: Can It Continue?
Prothena (PRTA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Zacks·17d ago
News Placeholder
More News
News Placeholder
Is Amarin (AMRN) Stock Outpacing Its Medical Peers This Year?
Here is how Amarin (AMRN) and ANI Pharmaceuticals (ANIP) have performed compared to their sector so far this year.
Zacks·29d ago
News Placeholder
RCKT Stock Rises as FDA Lifts Clinical Hold on Danon Disease Study
Rocket Pharmaceuticals' shares soar as the FDA lifts its clinical hold on the pivotal Danon disease gene therapy study.
Zacks·30d ago
News Placeholder
Allogene's Q2 Loss Narrower Than Expected, Pipeline in Focus
ALLO posts a narrower second-quarter 2025 loss. The company advances multiple CAR T programs targeting cancer and autoimmune diseases.
Zacks·1mo ago
News Placeholder
Amarin (AMRN) Could Find a Support Soon, Here's Why You Should Buy the Stock Now
After losing some value lately, a hammer chart pattern has been formed for Amarin (AMRN), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.
Zacks·1mo ago
News Placeholder
Is Amarin (AMRN) Outperforming Other Medical Stocks This Year?
Here is how Amarin (AMRN) and Bayer Aktiengesellschaft (BAYRY) have performed compared to their sector so far this year.
Zacks·1mo ago
News Placeholder
Amarin's Q2 Earnings & Revenues Trump Estimates, Stock Rises
AMRN beats second-quarter estimates for earnings. Revenues rise year over year on strong licensing gains.
Zacks·2mo ago
News Placeholder
Amarin Gears Up to Report Q2 Earnings: Here's What to Expect
AMRN braces up for second-quarter results as U.S. Vascepa sales are likely to slide, while growth in the EU looks imminent.
Zacks·2mo ago
News Placeholder
VKTX Stock Down on Wider-Than-Expected Loss in Q2, Nil Sales
Shares of Viking slide after Q2 loss widens to 58 cents per share on rising R&D and nil revenues, missing estimates by 14 cents.
Zacks·2mo ago
News Placeholder
Are Medical Stocks Lagging DexCom (DXCM) This Year?
Here is how DexCom (DXCM) and Amarin (AMRN) have performed compared to their sector so far this year.
Zacks·2mo ago

Latest AMRN News

View

Advertisement. Remove ads.

Advertisement. Remove ads.